SI2623497T1 - Megluminska sol 6-fluoro-3-hidroksi-2-pirazinkarboksamida - Google Patents

Megluminska sol 6-fluoro-3-hidroksi-2-pirazinkarboksamida

Info

Publication number
SI2623497T1
SI2623497T1 SI201130754T SI201130754T SI2623497T1 SI 2623497 T1 SI2623497 T1 SI 2623497T1 SI 201130754 T SI201130754 T SI 201130754T SI 201130754 T SI201130754 T SI 201130754T SI 2623497 T1 SI2623497 T1 SI 2623497T1
Authority
SI
Slovenia
Prior art keywords
fluoro
hydroxy
meglumine salt
pyrazine carboxamide
pyrazine
Prior art date
Application number
SI201130754T
Other languages
English (en)
Inventor
Keiko Takakura
Namika Nakamatsu
Sakiko Takeshima
Takayoshi Nakashima
Original Assignee
Toyama Chemical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co., Ltd. filed Critical Toyama Chemical Co., Ltd.
Publication of SI2623497T1 publication Critical patent/SI2623497T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SI201130754T 2010-09-30 2011-09-29 Megluminska sol 6-fluoro-3-hidroksi-2-pirazinkarboksamida SI2623497T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010221620 2010-09-30
EP11829249.9A EP2623497B1 (en) 2010-09-30 2011-09-29 Meglumine salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide
PCT/JP2011/072329 WO2012043696A1 (ja) 2010-09-30 2011-09-29 6-フルオロ-3-ヒドロキシ-2-ピラジンカルボキサミドのメグルミン塩

Publications (1)

Publication Number Publication Date
SI2623497T1 true SI2623497T1 (sl) 2016-04-29

Family

ID=45893135

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201130754T SI2623497T1 (sl) 2010-09-30 2011-09-29 Megluminska sol 6-fluoro-3-hidroksi-2-pirazinkarboksamida

Country Status (19)

Country Link
US (3) US20130217708A1 (sl)
EP (1) EP2623497B1 (sl)
JP (1) JP5936546B2 (sl)
CN (1) CN103209967B (sl)
CY (1) CY1117218T1 (sl)
DK (1) DK2623497T3 (sl)
ES (1) ES2561878T3 (sl)
HK (1) HK1183014A1 (sl)
HR (1) HRP20160218T1 (sl)
HU (1) HUE026794T2 (sl)
MY (1) MY161757A (sl)
PH (1) PH12015501328B1 (sl)
PL (1) PL2623497T3 (sl)
RS (1) RS54642B1 (sl)
SG (1) SG188662A1 (sl)
SI (1) SI2623497T1 (sl)
SM (1) SMT201600184B (sl)
TW (1) TWI507397B (sl)
WO (1) WO2012043696A1 (sl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
CA2794171C (en) 2010-03-24 2018-07-03 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
DK2623498T3 (en) 2010-09-30 2016-02-22 Toyama Chemical Co Ltd Sodium salt of 6-fluoro-3-hydroxy-2-pyrazinecarboxamide
EP2968498A4 (en) 2013-03-15 2016-09-07 Biogen Ma Inc PREPARATIONS CONTAINING FACTOR IX POLYPEPTIDE
EP3123090A4 (en) 2014-03-24 2017-12-13 Bioverativ Therapeutics Inc. Lyophilized factor ix formulations
CN104610153B (zh) * 2015-01-19 2017-02-22 沈阳中海生物技术开发有限公司 奥扎格雷葡甲胺盐及其组合物、制备方法和用途
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
TW201808291A (zh) * 2016-06-30 2018-03-16 富山化學工業股份有限公司 冷凍乾燥製劑之製造方法
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
CN111556752A (zh) * 2017-12-28 2020-08-18 富士胶片富山化学株式会社 冻干制剂的制造方法
JP7472116B2 (ja) 2018-11-19 2024-04-22 ジャズ ファーマシューティカルズ アイルランド リミテッド 耐アルコール性製剤
CN113473980A (zh) 2019-03-01 2021-10-01 弗拉梅尔爱尔兰有限公司 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物
CN111214446B (zh) * 2020-03-07 2022-02-25 瑞阳制药股份有限公司 一种供注射用法匹拉韦l-精氨酸盐冻干制剂
CN113750105A (zh) * 2020-12-11 2021-12-07 山东大学 一种法匹拉韦药用结合物及在制备抗病毒药物制剂中的应用
EP4265253A1 (en) 2020-12-18 2023-10-25 FUJIFILM Toyama Chemical Co., Ltd. Pharmaceutical composition
WO2022131112A1 (ja) 2020-12-18 2022-06-23 富士フイルム富山化学株式会社 医薬組成物
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4590269A (en) * 1984-03-29 1986-05-20 Syntex (U.S.A.) Inc. Process for preparing the cyclic phosphate ester of substituted 9-(1,3-dihydroxy-2-propoxymethyl)purines
IT1207994B (it) 1986-01-03 1989-06-01 Therapicon Srl Sali idrosulubili di composti adattivita' antiinfiammatoria ed analgesica, loro preparazione ed utilizzo in composizioni farmaceutiche.
JP3845876B2 (ja) * 1995-04-20 2006-11-15 アステラス製薬株式会社 ピラジン誘導体又はその塩を含有する安定な注射用組成物及びその製造方法
ES2393972T3 (es) 1998-01-07 2013-01-03 Meiji Seika Kaisha, Ltd. Composiciones de cefalosporina amorfa, cristalográficamente estable y procedimiento de preparación de las mismas
CN1154493C (zh) * 1998-08-20 2004-06-23 富山化学工业株式会社 含氮杂环羧酰胺衍生物或其盐以及含有二者的抗病毒药
CA2398620C (en) 2000-02-16 2009-06-23 Toyama Chemical Co., Ltd. Pyrazine derivatives, pharmaceutical compositions containing them, and intermediates therefor
DE10161077A1 (de) * 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion
PL1868581T3 (pl) * 2005-04-11 2012-08-31 Abbvie Inc Kompozycje farmaceutyczne słabo rozpuszczalnych leków o polepszonych profilach rozpuszczania
CA2677905C (en) 2007-02-16 2015-03-24 Toyama Chemical Co., Ltd. Pharmaceutical composition comprising pyrazine derivatives and neuraminidase inhibitors for treating influenza infections
JP5174365B2 (ja) * 2007-03-23 2013-04-03 第一三共株式会社 キノロン含有凍結乾燥製剤の製造方法
WO2009041473A1 (ja) 2007-09-27 2009-04-02 Toyama Chemical Co., Ltd. 6-フルオロ-3-ヒドロキシ-2-ピラジンカルボニトリルの有機アミン塩およびその製造法
EP2407166B1 (en) 2009-03-13 2013-08-21 Toyama Chemical Co., Ltd. Tablet and granulated powder containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide
DK2623498T3 (en) * 2010-09-30 2016-02-22 Toyama Chemical Co Ltd Sodium salt of 6-fluoro-3-hydroxy-2-pyrazinecarboxamide

Also Published As

Publication number Publication date
WO2012043696A1 (ja) 2012-04-05
RS54642B1 (en) 2016-08-31
HUE026794T2 (en) 2016-07-28
CN103209967B (zh) 2015-04-08
HK1183014A1 (en) 2013-12-13
SG188662A1 (en) 2013-05-31
ES2561878T3 (es) 2016-03-01
US20150266832A1 (en) 2015-09-24
JPWO2012043696A1 (ja) 2014-02-24
PH12015501328A1 (en) 2015-09-21
CN103209967A (zh) 2013-07-17
DK2623497T3 (en) 2016-03-21
US20150031885A1 (en) 2015-01-29
EP2623497A1 (en) 2013-08-07
MY161757A (en) 2017-05-15
CY1117218T1 (el) 2017-04-05
PH12015501328B1 (en) 2015-09-21
TWI507397B (zh) 2015-11-11
JP5936546B2 (ja) 2016-06-22
EP2623497B1 (en) 2016-01-20
TW201217343A (en) 2012-05-01
SMT201600184B (it) 2016-08-31
US9090571B2 (en) 2015-07-28
EP2623497A4 (en) 2014-03-26
PL2623497T3 (pl) 2016-07-29
HRP20160218T1 (hr) 2016-03-25
US20130217708A1 (en) 2013-08-22

Similar Documents

Publication Publication Date Title
HK1183014A1 (en) Meglumine salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide 6--3--2-
IL259958B (en) Heterocyclic glutaminase inhibitors
HK1243417A1 (zh) 吡啶酮和氮雜吡啶酮化合物及使用方法
HK1183015A1 (en) Sodium salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide 6--3--2-
IL237581B (en) Derivatives of 6-oxo-pyrazinopyrrolopyrimidines
ZA201303793B (en) Substituted quinoline compounds and methods of use
HK1178149A1 (en) Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use -4---
ZA201401653B (en) Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use
EP2772483A4 (en) 4-AMINOCARBAZOLE COMPOUND AND USE THEREOF
EP2663565A4 (en) HEZEROARYL COMPOUNDS AND METHOD FOR USE THEREOF
AP3268A (en) Co-crystals and salts of CCR3-inhibitors
EP2635587A4 (en) NOVEL 6-ARYLAMINOPYRIDONECARBOXAMIDES AS MEK INHIBITORS
ZA201206456B (en) Uses of dgati inhibitors
EP2625176A4 (en) SUBSTITUTED PYRIDAZINE CARBOXAMIDE COMPOUNDS
GB201111396D0 (en) Monitoring of livestock
ZA201209666B (en) Salts and polymorhs of dexrabeprazole
EP2709999A4 (en) QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE
EP2783690A4 (en) NEW USE OF NEOHESPERIDINE
HK1160777A1 (en) Novel use of neohesperidoside
IL243320A0 (en) Intermediates of teroarylpiperidine and piperazine derivatives
HU1000688D0 (en) Use of trifluoro-phal